Neurelis Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 185

Employees

  • Latest Deal Type
  • Debt

  • Latest Deal Amount
  • $150M

  • Investors
  • 8

Neurelis General Information

Description

Operator of neuroscience-based therapeutics intended to address unmet medical needs in epilepsy and rare central nervous system disorders. The company offers targeted drug delivery technologies applicable to a range of molecules, including proteins, peptides, and small molecules, enabling healthcare providers to improve treatment outcomes and enhance patient care.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3430 Carmel Mountain Road
  • Suite 300
  • San Diego, CA 92121
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3430 Carmel Mountain Road
  • Suite 300
  • San Diego, CA 92121
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurelis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - General 11-Aug-2021 $150M Completed Generating Revenue
6. Later Stage VC (Series D) 05-Mar-2021 Completed Generating Revenue
5. Later Stage VC (Series C) 06-Oct-2020 Completed Generating Revenue
4. Later Stage VC (Series B) 30-Dec-2016 Completed Clinical Trials - General
3. Later Stage VC (Series A) 02-Jul-2015 Completed Product Development
2. Merger/Acquisition 11-Jul-2014 $8.75M Cancelled Startup
1. Seed Round 30-Sep-2011 $4.5M $4.5M Completed Startup
To view Neurelis’s complete valuation and funding history, request access »

Neurelis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 19,815,059 $0.000100 8% $0.76 $0.76 1x $0.76 11.46%
Series A 37,744,121 $0.000100 8% $0.47 $0.47 1x $0.47 21.83%
To view Neurelis’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Neurelis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of neuroscience-based therapeutics intended to address unmet medical needs in epilepsy and rare central nervous
Drug Discovery
San Diego, CA
185 As of 2026

Clarksville, MD
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurelis Competitors (26)

One of Neurelis’s 26 competitors is NeuroNascent, a Venture Capital-Backed company based in Clarksville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NeuroNascent Venture Capital-Backed Clarksville, MD
Neurogene Formerly VC-backed New York, NY
Ovid Therapeutics Formerly VC-backed New York, NY
Minerva Neurosciences Formerly VC-backed Burlington, MA
Cognition Therapeutics Formerly VC-backed New York, NY
You’re viewing 5 of 26 competitors. Get the full list »

Neurelis Patents

Neurelis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026193385-A1 Treatment of early status epilepticus and prolonged seizures with intranasal diazepam Pending 13-Mar-2025
US-20250281479-A1 Treatment of cavernous angiomas with a 4-substituted piperidine derivative Pending 07-Mar-2024
WO-2025189104-A1 Treatment of cavernous angiomas with a 4-substituted piperidine derivative Pending 07-Mar-2024
WO-2025189104-A8 Treatment of cavernous angiomas with a 4-substituted piperidine derivative Pending 07-Mar-2024
WO-2025188992-A1 Oral film for rapid active delivery Pending 06-Mar-2024 A61K31/551
To view Neurelis’s complete patent history, request access »

Neurelis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurelis Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cormorant Asset Management PE/Buyout Minority
Decheng Capital Venture Capital Minority
OrbiMed Growth/Expansion Minority
Philos & Partners Family Office Minority
China Medical System Holdings Corporation Minority
You’re viewing 5 of 8 investors. Get the full list »

Neurelis Acquisitions (1)

Neurelis’s most recent deal was a Merger/Acquisition with Aegis Therapeutics. The deal was made on 03-Dec-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aegis Therapeutics 03-Dec-2018 Merger/Acquisition Drug Delivery
To view Neurelis’s complete acquisitions history, request access »

Neurelis FAQs

  • When was Neurelis founded?

    Neurelis was founded in 2007.

  • Where is Neurelis headquartered?

    Neurelis is headquartered in San Diego, CA.

  • What is the size of Neurelis?

    Neurelis has 185 total employees.

  • What industry is Neurelis in?

    Neurelis’s primary industry is Drug Discovery.

  • Is Neurelis a private or public company?

    Neurelis is a Private company.

  • What is Neurelis’s current revenue?

    The current revenue for Neurelis is .

  • How much funding has Neurelis raised over time?

    Neurelis has raised $382M.

  • Who are Neurelis’s investors?

    Cormorant Asset Management, Decheng Capital, OrbiMed, Philos & Partners, and China Medical System Holdings are 5 of 8 investors who have invested in Neurelis.

  • Who are Neurelis’s competitors?

    NeuroNascent, Neurogene, Ovid Therapeutics, Minerva Neurosciences, and Cognition Therapeutics are some of the 26 competitors of Neurelis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process